Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
Earnings margins to improve for mining specialist
Premium products drive margins yet shares fully valued.
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,200.60 | 12.10 | -0.13% |
| CAC 40 | 8,306.15 | 27.38 | 0.33% |
| DAX 40 | 26,006.53 | 39.87 | -0.15% |
| Dow JONES (US) | 53,414.25 | 271.86 | -0.51% |
| FTSE 100 | 10,822.13 | 8.96 | -0.08% |
| HKSE | 25,413.12 | 237.75 | -0.93% |
| NASDAQ | 26,506.99 | 77.07 | -0.29% |
| Nikkei 225 | 66,399.84 | 1,378.90 | 2.12% |
| NZX 50 Index | 13,942.83 | 31.35 | -0.22% |
| S&P 500 | 7,718.60 | 29.11 | -0.38% |
| S&P/ASX 200 | 9,010.90 | 12.50 | -0.14% |
| SSE Composite Index | 3,932.70 | 2.58 | 0.07% |